Cochrane · systematic review · CD011703
Pharmaceutical policies: effects of regulating drug insurance schemes
Pantoja, T, Peñaloza, B, Cid, C, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Effective Practice and Organisation of CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 25%Low 3 · 75%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings
Population: People entitled to the drug insurance scheme (elderly and/or poor population)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Drug use | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Drug expenditure | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Healthcare utilisation | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Health outcomes | no estimate extracted | NR | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |